Derivation Web

source_46d7422cae3c475f

by researka:v2 · 2026-07-02 00:13:12.322351+04:00

# Hypothesis-Generating Brief: Ramadan Fasting Effects — full paper
## Abstract

Evidence-honesty note: 44/48 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Ramadan fasting, practiced for 29–30 days annually by roughly 1.9 billion Muslims worldwide, imposes a pronounced diurnal intermittent fasting pattern whose cardiometabolic, glycemic, and contextual effects across healthy adults and clinical populations remain actively debated (Abdulrahman 2026, Abdelrahim 2021).

We conducted an AI-assisted structured evidence synthesis with a complete source-level audit trail, drawing on 48 curated primary studies, systematic reviews, and meta-analyses indexed for this topic, and we explicitly tagged direct versus indirect evidence and clinical versus mechanistic domains before integration.

We conclude that the evidence supports a context-dependent profile in which cardiometabolic improvements (notably blood pressure and HbA1c in pharmacologically treated T2DM) are the most reproducible clinical signal, whereas endothelial, immune, and contextual-other endpoints show directionally heterogeneous findings that the current 48-study base cannot reconcile, leaving boundary conditions — population, agent class, fasting duration seasonality — as the principal remaining uncertainties.

**Evidence-abstraction note.** The 48 retained reference papers are not 48 independent primary clinical trials: 44 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 4 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Introduction

This synthesis evaluates evidence on ramadan fasting effects across 48 included source papers and 2090 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 4 direct clinical sources, 43 adjacent, review, or context sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

Additional corpus sources included animal/preclinical evidence; the background evidence for ramadan fasting effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Elbarbary 2023, Hadrich 2025, Alwhaibi 2024 are interpreted separately from mechanistic studies such as Alasmari 2024, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic, contextual adjacent evidence, immune and inflammation outcome classes; null signals around the contextual adjacent evidence, safety and comorbidity, immune and inflammation outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-ramadan_fasting_effects-v06-DAILY-2026-07-01T20-01-05Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-01.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `Ramadan fasting effects aging`
- `Ramadan fasting effects older adults`
- `Ramadan fasting effects randomized controlled trial`
- `Ramadan fasting aging`
- `Ramadan fasting older adults`
- `Ramadan fasting randomized controlled trial`
- `fasting aging`
- `fasting older adults`
- `fasting randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses ramadan fasting effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 177 records in the receipt-candidate union, 57 were classified as source candidates and 48 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 177 |
| Classified source candidates | 57 |
| No extractable claims | 27 |
| None-only claim binding | 6 |
| Mixed partial-or-none claim-binding candidates | 59 |
| Partial-only claim-binding candidates | 16 |
| Strict high-confidence sources | 12 |
| Admitted final sources | 48 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune and inflammation, mechanism, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 48 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Source | Outcome class | Direction | Directness | Tier | Finding |
| --- | --- | --- | --- | --- | --- |
| Abdulkadir 2024 | Cardiometabolic | unclear | indirect | B2 | 12 extracted claim(s); source-level direction is the coded finding |
| AlJafar 2021 | Cardiometabolic | unclear | indirect | B2 | representative statistic P = 0.05; source-level statistic reported |
| Aldibbiat 2022 | Cardiometabolic | unclear | indirect | B2 | representative non-significant statistic P = 0.44; not treated as positive or negative directional support unless source direction is coded |
| Alwhaibi 2024 | Cardiometabolic | positive | direct | A1 | representative statistic P < 0.01; source-level statistic reported |
| Gholampoor 2024 | Cardiometabolic | positive | review | B1 | representative statistic P = 0.04; source-level statistic reported |
| Khalil 2025 | Cardiometabolic | unclear | indirect | B2 | representative statistic P = 0.037; source-level statistic reported |
| Kieu 2022 | Cardiometabolic | positive | review | B1 | representative statistic P = 0.010; source-level statistic reported |
| Kiran 2025 | Cardiometabolic | mixed | indirect | B2 | representative statistic P < 0.0001; source-level statistic reported |
| Lamti 2026 | Cardiometabolic | unclear | indirect | B2 | representative statistic P < 0.001; source-level statistic reported |
| Tahapary 2023 | Mechanism/Cardiometabolic (cell/in vitro) | unclear | indirect | B2 | representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Tsitsou 2022 | Cardiometabolic | mixed | review | B1 | representative statistic P < 0.001; source-level statistic reported |
| Uddin 2024 | Cardiometabolic | unclear | indirect | B2 | representative non-significant statistic P = 0.159; not treated as positive or negative directional support unless source direction is coded |
| Zainudin 2022 | Cardiometabolic | unclear | indirect | B2 | 20 extracted claim(s); source-level direction is the coded finding |
| Abassi 2024 | Contextual Adjacent Evidence | unclear | review | B2 | representative statistic P < 0.05; source-level statistic reported |
| Abdelrahim 2021 | Contextual Adjacent Evidence | null | review | B2 | 18 extracted claim(s); source-level direction is the coded finding |
| Abdulrahman 2026 | Contextual Adjacent Evidence | null | review | B2 | 3 extracted claim(s); source-level direction is the coded finding |
| AlTaiar 2025 | Contextual Adjacent Evidence | positive | review | B2 | representative statistic P < 0.007; source-level statistic reported |
| Baharuddin 2024 | Contextual Adjacent Evidence | null | indirect | B2 | 3 extracted claim(s); source-level direction is the coded finding |
| Besbes 2022 | Contextual Adjacent Evidence | null | review | B2 | 11 extracted claim(s); source-level direction is the coded finding |
| Bouida 2018 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative statistic P < 0.05; source-level statistic reported |
| Boujelbane 2022 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative statistic P = 0.035; source-level statistic reported |
| Chawla 2021 | Contextual Adjacent Evidence | unclear | review | B2 | representative statistic P < 0.05; source-level statistic reported |
| Demirli 2026 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative statistic P < 0.0083; source-level statistic reported |
| Elbarbary 2023 | Contextual Adjacent Evidence | unclear | direct | A1 | representative statistic P < 0.001; source-level statistic reported |
| Gad 2022 | Contextual Adjacent Evidence | positive | review | B2 | representative statistic P < 0.00001; source-level statistic reported |
| Glazier 2018 | Contextual Adjacent Evidence | null | review | B2 | representative non-significant statistic P = 0.99; not treated as positive or negative directional support unless source direction is coded |
| Hadrich 2025 | Contextual Adjacent Evidence | unclear | direct | A1 | representative non-significant statistic P = 0.5; not treated as positive or negative directional support unless source direction is coded |
| Harbuwono 2020 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative non-significant statistic P = 0.48; not treated as positive or negative directional support unless source direction is coded |
| Jo 2023 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative statistic P < 0.05; source-level statistic reported |
| Kalsekar 2024 | Biomarker/Adjacent Evidence | unclear | review | B2 | representative statistic p ≤ 0.001; source-level statistic reported |
| Kammoun 2022 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative statistic P = 0.000; source-level statistic reported |
| Khalifa 2025 | Contextual Adjacent Evidence | null | indirect | B2 | 1 extracted claim(s); source-level direction is the coded finding |
| Lauche 2024 | Contextual Adjacent Evidence | null | direct | A1 | representative statistic P < 0.05; source-level statistic reported |
| Lin 2024 | Contextual Adjacent Evidence | null | review | B2 | representative statistic P < 0.05; source-level statistic reported |
| Oosterwijk 2021 | Contextual Adjacent Evidence | unclear | review | B2 | representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Pieczynska-Zajac 2023 | Mechanism/Contextual Adjacent Evidence (animal/preclinical) | null | review | B2 | representative statistic P < 0.05; source-level statistic reported |
| Roky 2022 | Contextual Adjacent Evidence | null | review | B2 | 19 extracted claim(s); source-level direction is the coded finding |
| Tasdemir 2026 | Contextual Adjacent Evidence | unclear | indirect | B2 | representative statistic P < 0.001; source-level statistic reported |
| Mabrouk 2025 | Deficiency Prevalence | unclear | indirect | B2 | representative statistic P = 0.017; source-level statistic reported |
| Poursalehian 2024 | Biomarker/Adjacent Deficiency Prevalence | null | review | B2 | representative non-significant statistic P = 0.08; not treated as positive or negative directional support unless source direction is coded |
| Al-Jafar 2024 | Immune and Inflammation | negative | indirect | B2 | representative statistic P < 0.001; source-level statistic reported |
| DEMIRCI 2023 | Immune and Inflammation | positive | indirect | B2 | representative statistic P < 0.001; source-level statistic reported |
| Trabelsi 2022 | Immune and Inflammation | null | indirect | B2 | 13 extracted claim(s); source-level direction is the coded finding |
| Alasmari 2024 | Mechanism (rodent) | unclear | mechanistic | C1 | representative statistic P < 0.004; source-level statistic reported |
| Fashi 2021 | Muscle Function | unclear | indirect | B2 | representative statistic P = 0.002; source-level statistic reported |
| Damiani 2019 | Safety and Comorbidity | unclear | indirect | B2 | representative statistic P < 0.0001; source-level statistic reported |
| Ghrab 2025 | Safety and Comorbidity | unclear | indirect | B2 | representative non-significant statistic P = 0.208; not treated as positive or negative directional support unless source direction is coded |
| Loh 2019 | Safety and Comorbidity | null | review | B2 | 89 extracted claim(s); source-level direction is the coded finding |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Ramadan Fasting Effects / Contextual Adjacent Evidence | n=25; claims=1072 | significant source statistic in 18/25 sources; receipt-level direction coded unclear | 3 direct; 9 indirect; 13 review | limited corpus depth in this outcome class |
| Ramadan Fasting Effects / Cardiometabolic | n=13; claims=614 | significant source statistic in 10/13 sources; receipt-level direction coded unclear | 1 direct; 9 indirect; 3 review | limited corpus depth in this outcome class |
| Ramadan Fasting Effects / Immune and Inflammation | n=3; claims=112 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 3 indirect | limited corpus depth in this outcome class |
| Ramadan Fasting Effects / Safety and Comorbidity | n=3; claims=185 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Ramadan Fasting Effects / Deficiency Prevalence | n=2; claims=35 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Ramadan Fasting Effects / Mechanism | n=1; claims=36 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 mechanistic | single-source slice; hypothesis-generating |
| Ramadan Fasting Effects / Muscle Function | n=1; claims=36 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Contextual Adjacent Evidence: n=25; claims=1072; mixed signal in 13/25 sources | directness: 3 direct; 9 indirect; 13 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=13; claims=614; mixed signal in 8/13 sources | directness: 1 direct; 9 indirect; 3 review; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=3; claims=112; mixed signal in 1/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=3; claims=185; mixed signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Deficiency Prevalence: n=2; claims=35; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.
- Mechanism: n=1; claims=36; mixed signal in 1/1 sources | directness: 1 mechanistic; main limitation: no direct clinical anchor.

The retained ramadan fasting effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.

### Contextual Adjacent Evidence Outcomes

The contextual adjacent evidence packet includes 25 source-level summaries and 1072 high-confidence observations. Directional coding within this packet is null=10, positive=2, unclear=13, and directness coding is direct=3, indirect=9, review=13. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Directional coding within this packet is mixed=2, positive=3, unclear=8, and directness coding is direct=1, indirect=9, review=3.

Directional coding within this packet is null=1, positive=1, unclear=1, and directness coding is indirect=3.

Directional coding within this packet is null=1, unclear=2, and directness coding is indirect=2, review=1.

Directional coding within this packet is null=1, unclear=1, and directness coding is indirect=1, review=1.

Directional coding within this packet is unclear=1, and directness coding is mechanistic=1.

Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.

The section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement.

**Result-interpretation guardrail.**

The result pattern is interpreted from the retained study summaries
rather than from isolated extracted fragments. Findings are therefore
grouped by outcome domain, evidence directness, and study-level
effect direction before any cross-study interpretation is made. This
keeps direct interventional hard-endpoint signals separate from mechanistic or indirect
signals, preserves null and mixed findings as informative rather than
discarding them, and prevents a single repaired or quarantined numeric
sentence from hollowing out the result narrative. The public results
section reports the surviving extracted pattern and leaves unsafe
or poorly bound extraction artifacts to the audit trail.

This guardrail is deliberately numeric-free. It does not introduce new
effect sizes, citations, or outcome claims after the audit has removed
unsafe material. Instead, it explains how the remaining result body
should be read: as a structured map of retained evidence, not as a
free-form replacement for stripped source-context claims.

Descriptive findings remain separate from interpretation and endpoint-specific boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.



Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Immune and Inflammation Outcomes

Immune and Inflammation remains a separate Results slice for Ramadan Fasting Effects (n=3; claims=112; significant source statistic in 2/3 sources; receipt-level direction coded unclear; 3 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Al-Jafar 2024 (Metabolomics of Ramadan fasting and associated risk of chronic diseases; representative statistic P < 0.001; source-level statistic reported; outcome=Immune and Inflammation; direction=negative; directness=indirect; tier=B2).
- DEMIRCI 2023 (Improvement in endothelial function in hypertensive patients after Ramadan fasting: effects of cortisol; representative statistic p < 0.001; source-level statistic reported; outcome=Immune and Inflammation; direction=positive; directness=indirect; tier=B2).
- Trabelsi 2022 (Religious fasting and its impacts on individual, public, and planetary health: Fasting as a “religious health asset”; 13 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=null; directness=indirect; tier=B2).

### Cardiometabolic Outcomes

Cardiometabolic remains a separate Results slice for Ramadan Fasting Effects (n=13; claims=614; significant source statistic in 10/13 sources; receipt-level direction coded unclear; 1 direct; 9 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Alwhaibi 2024 (Effect of fasting-induced headache on calcitonin gene related peptide (CGRP) and other clinical biomarkers on the first; representative statistic p < 0.01; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=direct; tier=A1).
- Khalil 2025 (First-Time Usage of SGLT2 Inhibitors in Patients With Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety; representative statistic p = 0.037; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2).
- Kieu 2022 (A Systematic Review of Insulin Management Recommendations to Improve Glycemic Control and Reduce Hypoglycemic Events; representative statistic p = 0.010; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=review; tier=B1).
- Tsitsou 2022 (Effects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition, Glucose Responses, and Insulin; representative statistic p < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1).

### Safety and Comorbidity Outcomes

Safety and Comorbidity remains a separate Results slice for Ramadan Fasting Effects (n=3; claims=185; significant source statistic in 2/3 sources; receipt-level direction coded unclear; 2 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Damiani 2019 (The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting (“Ramadan Fasting”) on Hidradenitis; representative statistic p < 0.0001; source-level statistic reported; outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2).
- Ghrab 2025 (Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study); representative non-significant statistic p = 0.208; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2).
- Loh 2019 (Safety of Ramadan fasting in young patients with type 1 diabetes: A systematic review and meta‐analysis; 89 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2).

### Deficiency Prevalence Outcomes

Deficiency Prevalence remains a separate Results slice for Ramadan Fasting Effects (n=2; claims=35; significant source statistic in 1/2 sources; receipt-level direction coded unclear; 1 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Mabrouk 2025 (Ramadan Fasting Improves Health‐Related Quality of Life in Patients With Secondary Adrenal Insufficiency: A Prospective; representative statistic p = 0.017; source-level statistic reported; outcome=Deficiency Prevalence; direction=unclear; directness=indirect; tier=B2).
- Poursalehian 2024 (Impact of Ramadan fasting on serum levels of major endocrinology hormonal and biochemical parameters in healthy; representative non-significant statistic P = 0.08; not treated as positive or negative directional support unless source direction is coded; outcome=Biomarker/Adjacent Deficiency Prevalence; direction=null; directness=review; tier=B2).

### Mechanism Outcomes

Mechanism remains a separate Results slice for Ramadan Fasting Effects (n=1; claims=36; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Alasmari 2024 (Ramadan fasting model modulates biomarkers of longevity and metabolism in male obese and non-obese rats; representative statistic P < 0.004; source-level statistic reported; outcome=Mechanism (rodent); direction=unclear; directness=mechanistic; tier=C1).

### Muscle Function Outcomes

Muscle Function remains a separate Results slice for Ramadan Fasting Effects (n=1; claims=36; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Fashi 2021 (Effect of Acute Ramadan Fasting on Muscle Function and Buffering System of Male Athletes; representative statistic p = 0.002; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2).



We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Cross-Domain Synthesis

Additional corpus sources included animal/preclinical evidence; cross-domain interpretation of ramadan fasting effects is constrained by the relationship between clinical sources (Elbarbary 2023, Hadrich 2025, Alwhaibi 2024) and mechanistic studies (Alasmari 2024). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.

The main cross-domain pattern is the coexistence of positive signals in the cardiometabolic, contextual adjacent evidence, immune and inflammation outcome classes with null signals in the contextual adjacent evidence, safety and comorbidity, immune and inflammation outcome classes and negative signals in no dominant outcome class. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.

These pairwise disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

## Discussion

**Thesis:** Across 48 curated reference papers, the evidence base for Ramadan shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Ramadan broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 48 included sources. The evidence-tier distribution is: B2 (n=40), A1 (n=4), B1 (n=3), C1 (n=1). By directness, the breakdown is: indirect (n=25), review (n=18), direct (n=4), mechanistic (n=1). 38 of 48 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 2 distinct summaries across the source set: adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain any long-term mortality or hard cardiovascular endpoint trial of ramadan fasting in non-diabetic community-dwelling adults.

Several clinically salient outcomes are touched by only a single source in the corpus and therefore cannot be internally replicated. For each of these endpoints, a one-trial result cannot establish robustness, and any pooled estimate derived from a single source would carry the full weight of that study's design without an internal corroborator.

Population specificity further constrains the headline conclusions.

Endpoint scope in the corpus is narrow. Because the dominant outcome class is contextual other (37 of 48 sources tagged to that bucket), the corpus cannot adjudicate whether biomarker movement translates into event reduction — a general methodological caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005).

Finally, a mechanism-to-clinic gap pervades several clinically relevant claims. For each of these claims the corpus supplies a coherent mechanistic story but no clinical-outcome replication, so any translation from bench to bedside remains, in effect, a hypothesis rather than a finding.

### Residual uncertainty

The main limitation is not only the size of the retained corpus, but
also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some
are indirect or model-system evidence. The paper therefore avoids
treating all sources as equivalent. Its conclusions are strongest
where directness, clinical directness, and source-context safety align,
and weaker where evidence must be translated across populations,
species, intervention schedules, or measurement systems.

The limitations identify evidence gaps, missing populations, indirect endpoints, and unresolved follow-up windows. interpretation.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 48 included sources. The evidence tiers are B2 (n=40), A1 (n=4), B1 (n=3), C1 (n=1), and directness is indirect (n=25), review (n=18), direct (n=4), mechanistic (n=1). These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 48 included sources on Ramadan Fasting Effects across 7 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between DEMIRCI 2023 and Trabelsi 2022 on immune and inflammation (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Kieu 2022, Tsitsou 2022, Gholampoor 2024) emphasize convergent signals on Ramadan Fasting Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| immune and inflammation | 0 | 3 | null, positive, unclear | conflict-resolution gap |
| mechanism | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| muscle function | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 1 | 12 | mixed, positive, unclear | replication gap |
| deficiency prevalence | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 3 | 22 | null, positive, unclear | conflict-resolution gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | immune and inflammation: conflict-resolution gap | 0 direct and 3 indirect sources; direction profile: null, positive, unclear |
| P2 | mechanism: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P4 | cardiometabolic: replication gap | 1 direct and 12 indirect sources; direction profile: mixed, positive, unclear |
| P5 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for Ramadan Fasting Effects should target the **immune and inflammation** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Additional corpus sources included animal/preclinical evidence; Elbarbary 2023; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Hadrich 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Alwhaibi 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.0001.
- Lauche 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Kieu 2022; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.0001.
- Tsitsou 2022; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Gholampoor 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.04.
- Pieczynska-Zajac 2023; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null.
- Loh 2019; tier=B2; directness=review; endpoint=safety comorbidity; direction=null.
- Khalil 2025; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Additional corpus sources included animal/preclinical evidence; severity 4 null vs positive: DEMIRCI 2023 vs Trabelsi 2022; DEMIRCI 2023 (positive on immune) vs Trabelsi 2022 (null on immune) — partial conflict
- Severity 4 null vs positive: Lin 2024 vs AlTaiar 2025; AlTaiar 2025 (positive on contextual other) vs Lin 2024 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Lin 2024 vs Gad 2022; Gad 2022 (positive on contextual other) vs Lin 2024 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Pieczynska-Zajac 2023 vs AlTaiar 2025; AlTaiar 2025 (positive on contextual other) vs Pieczynska-Zajac 2023 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Pieczynska-Zajac 2023 vs Gad 2022; Gad 2022 (positive on contextual other) vs Pieczynska-Zajac 2023 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Baharuddin 2024 vs AlTaiar 2025; AlTaiar 2025 (positive on contextual other) vs Baharuddin 2024 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Baharuddin 2024 vs Gad 2022; Gad 2022 (positive on contextual other) vs Baharuddin 2024 (null on contextual other) — partial conflict
- Severity 4 null vs positive: AlTaiar 2025 vs Khalifa 2025; AlTaiar 2025 (positive on contextual other) vs Khalifa 2025 (null on contextual other) — partial conflict


## References

- **Elbarbary 2023.** _Mitigating iftar-related glycemic excursions in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed loop system: a randomized clinical trial for adjunctive oral vildagliptin therapy during Ramadan fasting._ Diabetology & Metabolic Syndrome, 2023. DOI: 10.1186/s13098-023-01232-5 PMID: 38057844.
- **Pieczynska-Zajac 2023.** _The effects of time-restricted eating and Ramadan fasting on gut microbiota composition: a systematic review of human and animal studies._ Nutrition Reviews, 2023. DOI: 10.1093/nutrit/nuad093 PMID: 37528052.
- **Hadrich 2025.** _Randomized trial of the effect of esomeprazole on functional dyspepsia during Ramadan fasting._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-17532-x PMID: 41120363.
- **Loh 2019.** _Safety of Ramadan fasting in young patients with type 1 diabetes: A systematic review and meta‐analysis._ Journal of Diabetes Investigation, 2019. DOI: 10.1111/jdi.13054 PMID: 30938074.
- **Khalil 2025.** _First-Time Usage of SGLT2 Inhibitors in Patients With Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety._ Journal of Diabetes Research, 2025. DOI: 10.1155/jdr/4321423 PMID: 40322737.
- **Boujelbane 2022.** _Time-restricted feeding and cognitive function in sedentary and physically active elderly individuals: Ramadan diurnal intermittent fasting as a model._ Frontiers in Nutrition, 2022. DOI: 10.3389/fnut.2022.1041216 PMID: 36438750.
- **Kieu 2022.** _A Systematic Review of Insulin Management Recommendations to Improve Glycemic Control and Reduce Hypoglycemic Events During Ramadan Fasting in Patients With Insulin-Requiring Type 2 Diabetes._ Frontiers in Nutrition, 2022. DOI: 10.3389/fnut.2022.846600 PMID: 35634376.
- **Kammoun 2022.** _Effects of Walking Football During Ramadan Fasting on Heart Rate Variability and Physical Fitness in Healthy Middle-Aged Males._ American Journal of Men's Health, 2022. DOI: 10.1177/15579883221103418 PMID: 35723054.
- **Tsitsou 2022.** _Effects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition, Glucose Responses, and Insulin Resistance: A Systematic Review of Randomized Controlled Trials._ Nutrients, 2022. DOI: 10.3390/nu14224778 PMID: 36432465.
- **Alwhaibi 2024.** _Effect of fasting-induced headache on calcitonin gene related peptide (CGRP) and other clinical biomarkers on the first day of Ramadan: Sub-analysis from a randomized open label clinical trial._ The Journal of Headache and Pain, 2024. DOI: 10.1186/s10194-024-01886-0 PMID: 39415097.
- **Uddin 2024.** _Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study._ Journal of Comparative Effectiveness Research, 2024. DOI: 10.57264/cer-2023-0132 PMID: 38294337.
- **Lauche 2024.** _Effects of Modified Ramadan Fasting on Mental Well-Being and Biomarkers in Healthy Adult Muslims — A Randomised Controlled Trial._ International Journal of Behavioral Medicine, 2024. DOI: 10.1007/s12529-024-10296-0 PMID: 38777939.
- **Demirli 2026.** _Effects of protein sources at sahur on anaerobic power and strength during Ramadan in combat sport athletes: A single blind, randomized, placebo-controlled, counterbalanced crossover study design._ PLOS One, 2026. DOI: 10.1371/journal.pone.0340961 PMID: 41824520.
- **Al-Jafar 2024.** _Metabolomics of Ramadan fasting and associated risk of chronic diseases._ The American Journal of Clinical Nutrition, 2024. DOI: 10.1016/j.ajcnut.2024.01.019 PMID: 38301826.
- **AlTaiar 2025.** _Impacts of Ramadan fasting during pregnancy on pregnancy and birth outcomes: An umbrella review._ International Journal of Gynaecology and Obstetrics, 2025. DOI: 10.1002/ijgo.16127 PMID: 39785103.
- **Damiani 2019.** _The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting (“Ramadan Fasting”) on Hidradenitis Suppurativa: Insights from a Multicenter, Observational, Cross-Over, Pilot, Exploratory Study._ Nutrients, 2019. DOI: 10.3390/nu11081781 PMID: 31374976.
- **Gad 2022.** _Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitors: A systematic review and meta‐analysis._ Journal of Diabetes Investigation, 2022. DOI: 10.1111/jdi.13741 PMID: 34953158.
- **Tasdemir 2026.** _Maternal Ramadan fasting and fetal cardiac function: subclinical hemodynamic alterations revealed by doppler evaluation._ BMC Pregnancy and Childbirth, 2026. DOI: 10.1186/s12884-026-08683-4 PMID: 41645092.
- **Lamti 2026.** _Effects of fasting on endothelial function in type 2 diabetes mellitus patients: cohort study._ Frontiers in Cardiovascular Medicine, 2026. DOI: 10.3389/fcvm.2025.1646786 PMID: 41573513.
- **Ghrab 2025.** _Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study)._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1565094 PMID: 41031153.
- **Kiran 2025.** _Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study._ BMC Endocrine Disorders, 2025. DOI: 10.1186/s12902-025-02134-5 PMID: 41454305.
- **AlJafar 2021.** _Effect of Religious Fasting in Ramadan on Blood Pressure: Results From LORANS (London Ramadan Study) and a Meta‐Analysis._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021. DOI: 10.1161/JAHA.120.021560 PMID: 34619991.
- **Alasmari 2024.** _Ramadan fasting model modulates biomarkers of longevity and metabolism in male obese and non-obese rats._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-79557-y PMID: 39567585.
- **Fashi 2021.** _Effect of Acute Ramadan Fasting on Muscle Function and Buffering System of Male Athletes._ Healthcare, 2021. DOI: 10.3390/healthcare9040397 PMID: 33916095.
- **DEMIRCI 2023.** _Improvement in endothelial function in hypertensive patients after Ramadan fasting: effects of cortisol._ Turkish Journal of Medical Sciences, 2023. DOI: 10.55730/1300-0144.5603 PMID: 37476871.
- **Bouida 2018.** _Effects of Ramadan fasting on aspirin resistance in type 2 diabetic patients._ PLoS ONE, 2018. DOI: 10.1371/journal.pone.0192590 PMID: 29529091.
- **Aldibbiat 2022.** _Use of automated insulin delivery systems in people with type 1 diabetes fasting during Ramadan: An observational study._ Journal of Diabetes Investigation, 2022. DOI: 10.1111/jdi.13720 PMID: 34826214.
- **Glazier 2018.** _The effect of Ramadan fasting during pregnancy on perinatal outcomes: a systematic review and meta-analysis._ BMC Pregnancy and Childbirth, 2018. DOI: 10.1186/s12884-018-2048-y PMID: 30359228.
- **Abassi 2024.** _Ramadan fasting as a form of time-restricted eating during pregnancy and long-term health effects in offspring: a narrative systematic review._ BMC Public Health, 2024. DOI: 10.1186/s12889-024-20367-2 PMID: 39696154.
- **Tahapary 2023.** _Differential effect of ramadan fasting on intercellular adhesion molecule-1 (ICAM-1) in diabetes mellitus and non-diabetes mellitus patients._ Heliyon, 2023. DOI: 10.1016/j.heliyon.2023.e17273 PMID: 37455951.
- **Mabrouk 2025.** _Ramadan Fasting Improves Health‐Related Quality of Life in Patients With Secondary Adrenal Insufficiency: A Prospective Interventional Case‐Control Study._ Clinical Endocrinology, 2025. DOI: 10.1111/cen.15286 PMID: 40452492.
- **Harbuwono 2020.** _The impact of Ramadan fasting on glucose variability in type 2 diabetes mellitus patients on oral anti diabetic agents._ PLoS ONE, 2020. DOI: 10.1371/journal.pone.0234443 PMID: 32598395.
- **Oosterwijk 2021.** _Ramadan Fasting during Pregnancy and Health Outcomes in Offspring: A Systematic Review._ Nutrients, 2021. DOI: 10.3390/nu13103450 PMID: 34684451.
- **Zainudin 2022.** _Walking Football During Ramadan Fasting for Cardiometabolic and Psychological Health Benefits to the Physically Challenged and Aged Populations._ Frontiers in Nutrition, 2022. DOI: 10.3389/fnut.2021.779863 PMID: 35087855.
- **Roky 2022.** _Sex as a Biological Factor in the Changes in Disease Patients During Ramadan Intermittent Fasting: A Systematic Review._ Frontiers in Nutrition, 2022. DOI: 10.3389/fnut.2022.908674 PMID: 35845800.
- **Jo 2023.** _The Alteration of the Gut Microbiome during Ramadan Offers a Novel Perspective on Ramadan Fasting: A Pilot Study._ Microorganisms, 2023. DOI: 10.3390/microorganisms11082106 PMID: 37630666.
- **Abdelrahim 2021.** _Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies._ Frontiers in Endocrinology, 2021. DOI: 10.3389/fendo.2021.624423 PMID: 33763029.
- **Lin 2024.** _The impacts of Ramadan fasting for patients with non-alcoholic fatty liver disease (NAFLD): a systematic review._ Frontiers in Nutrition, 2024. DOI: 10.3389/fnut.2023.1315408 PMID: 38303901.
- **Trabelsi 2022.** _Religious fasting and its impacts on individual, public, and planetary health: Fasting as a “religious health asset” for a healthier, more equitable, and sustainable society._ Frontiers in Nutrition, 2022. DOI: 10.3389/fnut.2022.1036496 PMID: 36505246.
- **Abdulkadir 2024.** _Effect of fasting on cardiovascular risk factors among healthy adult Muslims attending primary care, Kano, Northern Nigeria._ BMC Cardiovascular Disorders, 2024. DOI: 10.1186/s12872-024-04325-9 PMID: 39543511.
- **Chawla 2021.** _The Window Matters: A Systematic Review of Time Restricted Eating Strategies in Relation to Cortisol and Melatonin Secretion._ Nutrients, 2021. DOI: 10.3390/nu13082525 PMID: 34444685.
- **Besbes 2022.** _The Impacts of Ramadan Intermittent Fasting on Saliva Flow-Rate and Metabolic Data: A Systematic Review._ Frontiers in Nutrition, 2022. DOI: 10.3389/fnut.2022.873502 PMID: 35464020.
- **Poursalehian 2024.** _Impact of Ramadan fasting on serum levels of major endocrinology hormonal and biochemical parameters in healthy non-athlete adults: A systematic review and meta-analyses._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0299695 PMID: 38781203.
- **Kalsekar 2024.** _Effect of calorie restriction and intermittent fasting on glucose homeostasis, lipid profile, inflammatory, and hormonal markers in patients with polycystic ovary syndrome: a systematic review._ Frontiers in Nutrition, 2024. DOI: 10.3389/fnut.2024.1362226 PMID: 38646104.
- **Baharuddin 2024.** _Metabolism and diabetes in Ramadan fasting: Exploring health trends and relationships through systematic literature network analysis._ Narra J, 2024. DOI: 10.52225/narra.v4i2.850 PMID: 39280308.
- **Abdulrahman 2026.** _The effect of fasting Ramadan on type 2 diabetes: A narrative review and practice update._ Journal of Family Medicine and Primary Care, 2026. DOI: 10.4103/jfmpc.jfmpc_1118_25 PMID: 42023379.
- **Gholampoor 2024.** _The effect of observing religious or faith-based fasting on cardiovascular disease risk factors: A systematic review and meta-analysis._ Nutr Metab Cardiovasc Dis, 2024. DOI: 10.1016/j.numecd.2024.02.002 PMID: 38508992.
- **Khalifa 2025.** _Intermittent fasting and liver disease: Insights from the Ramadan model._ Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association, 2025. DOI: 10.4103/sjg.sjg_120_25 PMID: 41186505.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "ac0ebbeb-7974-4c5e-9c27-0fa130ee0523",
  "title": "Hypothesis-Generating Brief: Ramadan Fasting Effects \u2014 full paper"
}